FDA to take a harder look at custom blending of drugs
Pharmacies grow concerned as agency decides 'compounding' creates unapproved therapies
WASHINGTON -- The Food and Drug Administration has reversed its hands-off stance toward pharmacists who custom-blend drugs using bulk ingredients and is pledging stricter oversight of their work, known as compounding. (Full article: 776 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
